Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares trading hands. The stock had previously closed at $52.83.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright raised shares of Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.
Check Out Our Latest Analysis on Basilea Pharmaceutica
Basilea Pharmaceutica Stock Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Stories
- Five stocks we like better than Basilea Pharmaceutica
- How to Use the MarketBeat Dividend Calculator
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- Best Stocks Under $5.00
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
